Sanofi

96.070+0.1700+0.18%Vol 2001Y Perf -3.69%
Dec 2nd, 2021 20:10
BID0.0000 ASK0.0000
Open96.070 Previous Close95.900
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     56.54
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     59.75
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★+     48.52
Price Range Ratio 52W %
30.63 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha0.00 Standard Deviation0.05
Beta0.33 

Today's Price Range

96.07096.070

52W Range

88.750112.65

5 Year PE Ratio Range

0.000043.000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.64%
1 Month
-6.41%
3 Months
-5.72%
6 Months
-6.67%
1 Year
-3.69%
3 Years
7.47%
5 Years
19.86%
10 Years
0.00%

TickerPriceChg.Chg.%
SNYNF96.0700.17000.18
AAPL161.84-1.9200-1.17
GOOG2 850.41-25.1200-0.87
MSFT323.01-6.4800-1.97
XOM60.89-0.3900-0.64
WFC47.75-1.1600-2.37
JNJ159.382.29001.46
FB306.84-3.5500-1.14
GE92.77-2.4600-2.58
JPM158.29-2.9200-1.81
Financial StrengthValueIndustryS&P 500US Markets
0.90
1.50
0.23
0.34
20.70
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
67.10
20.60
29.70
15.80
16.18
RevenueValueIndustryS&P 500US Markets
45.60B
36.09
7.04
2.37
DividendsValueIndustryS&P 500US Markets
3.98
3.84
1.64
1.70
Payout ratio69.00
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume200
Shares Outstanding0
Shares Float1.12B
Trades Count8
Dollar Volume14.95M
Avg. Volume12.57K
Avg. Weekly Volume5.34K
Avg. Monthly Volume29.58K
Avg. Quarterly Volume20.98K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Sanofi

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of sales.

CEO: Olivier Brandicourt

Telephone: +33 153774000

Address: 54, Rue La Boétie, Paris 75008, , FRA

Number of employees: 100 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

59%41%

TipRanks News for SNYNF

Mon, 29 Nov 2021 12:25 GMT Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Novavax (NVAX)

- TipRanks. All rights reserved.

Thu, 28 Oct 2021 12:47 GMT Sanofi (SNYNF) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Tue, 10 Aug 2021 09:54 GMT Sanofi (SNYNF) Receives a Buy from J.P. Morgan

- TipRanks. All rights reserved.

Tue, 10 Aug 2021 09:54 GMT Sanofi (SNYNF) Gets a Buy Rating from Goldman Sachs

- TipRanks. All rights reserved.

News